Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2005
03/31/2005CA2539554A1 Phenylacetic acid derivative, process for producing the same, and use
03/31/2005CA2539361A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
03/31/2005CA2539359A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
03/31/2005CA2539358A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteopenia or male osteoporosis
03/31/2005CA2539357A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
03/31/2005CA2539230A1 Combinations of a vegf receptor inhibitor with other therapeutic agents
03/31/2005CA2538993A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
03/31/2005CA2538756A1 Polymorphic forms of a known antihyperlipemic agent
03/31/2005CA2538291A1 Substituted sulfonamides
03/30/2005EP1518554A1 Pharmaceutical composition for the treatment of hyperhomocysteinemia
03/30/2005EP1517924A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
03/30/2005EP1517909A2 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
03/30/2005EP1517908A2 Novel benzimidazole derivatives
03/30/2005EP1517907A2 Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
03/30/2005EP1517905A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases
03/30/2005EP1517897A2 Benzimidazole compounds and their use as estrogen agonists/antagonists
03/30/2005EP1517892A1 Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof
03/30/2005EP1517891A1 Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof
03/30/2005EP1517890A1 Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
03/30/2005EP1517889A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
03/30/2005EP1517883A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
03/30/2005EP1517882A1 Amide linker peroxisome proliferator activated receptor modulators
03/30/2005EP1517697A1 Acidic insulin preparations with improved stability
03/30/2005EP1517694A1 Plant extracts
03/30/2005EP1517680A1 Benzoic acid derivatives as modulators of ppar alpha and gamma
03/30/2005EP1517679A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
03/30/2005EP1517676A1 Oral dosage forms comprising fenofibrate
03/30/2005EP1517619A1 Satiety inducing composition
03/30/2005EP1399136B1 Process for the preparation of dispersions
03/30/2005EP1390025B1 Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders
03/30/2005EP1307182B1 Pharmaceutical composition for transdermal delivery of befloxatone
03/30/2005EP1246692B1 Templating of uncharged solid particles by polymer multilayers
03/30/2005EP1237898B1 N?6 heterocyclic 8-modified adenosine derivatives
03/30/2005EP1194140B1 Pharmaceutical composition containing fenofibrate and preparation method
03/30/2005EP1105378B1 Quinazoline derivatives
03/30/2005EP1091942B1 Potassium channel blocking agents
03/30/2005EP1075467B1 Pyrazole derivatives as p-38 map kinase inhibitors
03/30/2005EP0929232B1 Method of improving the growth or the efficiency of feed conversion of an animal and compositions for use therein
03/30/2005CN1602425A Therapeutic and diagnostic uses of antibody specificity profiles
03/30/2005CN1602360A Methods of increasing endogenous erythropoietin (EPO)
03/30/2005CN1602317A Angiopoietin-2 specific binding agents
03/30/2005CN1602311A Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase
03/30/2005CN1602307A Substituted 6h-dibenzo[c, h]chromenes as estrogenic agents
03/30/2005CN1602295A Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same
03/30/2005CN1602292A Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists
03/30/2005CN1602199A Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
03/30/2005CN1602191A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
03/30/2005CN1602187A Valdecoxib-based composition prepared by spray drying process and exhibiting rapid oral dissolution
03/30/2005CN1602159A Composition for promotion of bone growth and maintenance of bone health
03/30/2005CN1600360A Soft capsule of decoction of four ingredients possessing effect of enriching blood and regulating menstruation and preparation method
03/30/2005CN1600359A Capsule for curing high blood fat and preparation method
03/30/2005CN1600358A Combination of medication for curing hyperlipemia, arteriosclerosis, coronary heart disease and fatty liver
03/30/2005CN1600351A Medication for treating peripheral nervous lesion caused by diabetes
03/30/2005CN1600332A Method for preparing soft capsule of adjusting blood sugar and blood fat
03/30/2005CN1600322A Combination of propolis, preparation method and usage
03/30/2005CN1600305A Oral liquid prepared-from extractive of ginkgo leaf for anti heart and cerebral ischemia, and reducing blood fat and for enhancing memory
03/30/2005CN1600302A Combination of medicine containing ferric citrate, medicine level ferric citrate, preparation method, and diet nutrition containing ferric citrate in medicine level
03/30/2005CN1600139A Medicinal tea
03/30/2005CN1194741C Erigreron Breviscapus compound preparation
03/30/2005CN1194715C Processing method medicinal powder for diabetes
03/30/2005CN1194711C Instant powder for preventing and treating nutritional iron deficiency anemia
03/30/2005CN1194706C Medicine composition for treating diabetes
03/30/2005CN1194691C Composition for curing hyperlipemia
03/30/2005CN1194674C Novel diphenylethylene compounds
03/30/2005CN1194669C Nutritive sustained release ball for ruminant
03/29/2005US6872853 Bioavailability; reacting sertratineamine with hydrogen chloride
03/29/2005US6872851 Melatonergic receptors; antiinflammatory agents; anticancer agents
03/29/2005US6872738 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
03/29/2005US6872737 Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis
03/29/2005US6872733 Benzimidazolone compounds
03/29/2005US6872732 Heterocyclic derivatives and medicinal use thereof
03/29/2005US6872731 Imidazo-pyridine derivatives as ligands for GABA receptors
03/29/2005US6872730 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
03/29/2005US6872719 Antiinflammatory agents; autoimmune disease
03/29/2005US6872717 Pharmacological uses of azetidine derivatives
03/29/2005US6872712 Cyclic glycerophosphates and analogs thereof
03/29/2005US6872711 β-substituted β-aminoethyl phosphonate derivatives
03/29/2005US6872706 Hypoglycemic agents; antidiabetic agents; dietetics
03/29/2005US6872391 Nucleotide sequences coding polypeptide for use in the treatment of eating disorders
03/29/2005CA2335186C Pyrrolo[2,3-d]pyrimidine compounds
03/29/2005CA2301732C Therapeutic combinations
03/29/2005CA2268870C Heterocyclic carboxamides
03/29/2005CA2180950C Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
03/29/2005CA2176042C Alpha-aryl or heteroaryl-substituted amide ester acat inhibitors
03/24/2005WO2005026741A2 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
03/24/2005WO2005026315A2 Method for producing insulin from a natural source and insulin
03/24/2005WO2005026160A1 Crystal of heterocyclic compound
03/24/2005WO2005026159A1 Benzoxazole acetonitriles
03/24/2005WO2005026127A1 Plasminogen activator inhibitor-1 inhibitor
03/24/2005WO2005026125A1 Quinoline compounds and pharmaceutical compositions containing them
03/24/2005WO2005026116A1 Crystalline forms of `r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-`(phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid
03/24/2005WO2005025681A2 A system for and a method of manufacturing personal golf putters
03/24/2005WO2005025673A1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent
03/24/2005WO2005025602A1 METHODS FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C-EPSILON (PKCϵ) AND METHOD OF TREATMENT OF ABERRANT GLUCOSE METABOLISM ASSOCIATED THEREWITH
03/24/2005WO2005025574A2 PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES.
03/24/2005WO2005025570A1 Use of antagonists of hepatic sympathetic nerve activity
03/24/2005WO2005025567A1 Benzothiazole derivatives for the treatment of diabetes
03/24/2005WO2005025558A1 Sulfonamide derivatives for the treatment of diabetes
03/24/2005WO2005025504A2 Modulators of calcitonin and amylin activity
03/24/2005WO2005011657A3 Piperazine derivatives and their use as therapeutic agents
1 ... 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 ... 1298